RYTM stock forecast
Our latest prediction for Rhythm Pharmaceuticals, Inc.'s stock price was made on the June 29, 2020 when the stock price was at 21.79$.
In the short term (2weeks), RYTM's stock price should underperform the market by -2.83%. During that period the price should oscillate between -12.18% and +10.92%.
In the medium term (3months), RYTM's stock price should underperform the market by -4.11%. During that period the price should oscillate between -37.80% and +31.07%.Get email alerts
Create a solid portfolio with RYTM
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -3.80$ per share.
The book value per share is 8.32$
Three months stock forecastJune 29, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|